Holdings of Nomura Healthcare Fund
Delaware Group Equity Funds IV · Original filing · Compare with another fund · Report an error
- Net assets
- 665M $ including 620.3M $ in equities, 93.3 %
- Positions
- 96 in 13 countries
- Top ten
- 42.6 % of net assets
- Filed on
- Mar 31, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | UCB SA | 130,137 | 39.2M $ | 5.90 % |
| 2 | Regeneron Pharmaceuticals, Inc. | 47,000 | 36.3M $ | 5.46 % |
| 3 | Pfizer Inc | 1,145,000 | 32.2M $ | 4.84 % |
| 4 | Gilead Sciences Inc | 210,000 | 29.3M $ | 4.40 % |
| 5 | AbbVie Inc | 125,000 | 27.2M $ | 4.09 % |
| 6 | Merck & Co Inc | 215,000 | 25.9M $ | 3.89 % |
| 7 | AstraZeneca PLC | 131,243 | 25.7M $ | 3.86 % |
| 8 | Chugai Pharmaceutical Co Ltd | 450,000 | 24.8M $ | 3.73 % |
| 9 | Eli Lilly & Co | 26,000 | 23.9M $ | 3.60 % |
| 10 | UnitedHealth Group Inc | 70,000 | 18.9M $ | 2.85 % |
| 11 | Elevance Health Inc | 63,000 | 18.4M $ | 2.77 % |
| 12 | Amgen Inc | 47,000 | 16.5M $ | 2.49 % |
| 13 | Viatris Inc | 1,170,018 | 15.8M $ | 2.38 % |
| 14 | Boston Scientific Corp | 250,000 | 15.7M $ | 2.36 % |
| 15 | Halozyme Therapeutics Inc | 220,000 | 14.2M $ | 2.14 % |
| 16 | Sanofi SA | 120,000 | 11.6M $ | 1.74 % |
| 17 | Vertex Pharmaceuticals Inc | 25,000 | 11.2M $ | 1.68 % |
| 18 | Illumina Inc | 90,000 | 11.1M $ | 1.67 % |
| 19 | Viking Therapeutics Inc | 330,100 | 10.7M $ | 1.62 % |
| 20 | Alkermes PLC | 290,000 | 10.3M $ | 1.54 % |
| 21 | Alnylam Pharmaceuticals Inc | 30,000 | 9.9M $ | 1.49 % |
| 22 | Fannie Mae | 1,300,000 | 9.4M $ | 1.42 % |
| 23 | Roivant Sciences Ltd | 338,181 | 9.4M $ | 1.41 % |
| 24 | Neurocrine Biosciences Inc | 70,000 | 9.2M $ | 1.39 % |
| 25 | Cogent Biosciences Inc | 230,000 | 8.9M $ | 1.33 % |
| 26 | Arcus Biosciences Inc | 379,100 | 8.2M $ | 1.23 % |
| 27 | Incyte Corp | 80,000 | 7.5M $ | 1.13 % |
| 28 | Zimmer Biomet Holdings Inc | 80,000 | 7.2M $ | 1.09 % |
| 29 | Tarsus Pharmaceuticals Inc | 100,000 | 7M $ | 1.05 % |
| 30 | Freddie Mac | 1,050,000 | 6.7M $ | 1.01 % |
| 31 | Quest Diagnostics Inc | 30,000 | 5.9M $ | 0.88 % |
| 32 | BioMarin Pharmaceutical Inc | 100,000 | 5.6M $ | 0.85 % |
| 33 | CVS Health Corp | 75,000 | 5.4M $ | 0.81 % |
| 34 | AnaptysBio Inc | 93,732 | 5.2M $ | 0.78 % |
| 35 | Biogen Inc | 28,000 | 5.1M $ | 0.77 % |
| 36 | Abivax SA | 45,000 | 5M $ | 0.75 % |
| 37 | Stryker Corp | 15,000 | 4.9M $ | 0.74 % |
| 38 | Johnson & Johnson | 20,000 | 4.9M $ | 0.74 % |
| 39 | Vir Biotechnology Inc | 500,000 | 4.5M $ | 0.67 % |
| 40 | GRAIL Inc | 85,000 | 4.4M $ | 0.66 % |
| 41 | Rigel Pharmaceuticals Inc | 160,000 | 4.3M $ | 0.65 % |
| 42 | uniQure NV | 258,211 | 4.2M $ | 0.63 % |
| 43 | Syndax Pharmaceuticals Inc | 180,000 | 4.2M $ | 0.63 % |
| 44 | Madrigal Pharmaceuticals Inc | 7,000 | 3.7M $ | 0.55 % |
| 45 | Theravance Biopharma Inc | 208,783 | 3.4M $ | 0.51 % |
| 46 | Monte Rosa Therapeutics Inc | 200,000 | 3.3M $ | 0.49 % |
| 47 | Immunovant Inc | 122,100 | 3M $ | 0.46 % |
| 48 | Structure Therapeutics Inc | 58,000 | 2.8M $ | 0.42 % |
| 49 | Perrigo Co PLC | 230,000 | 2.5M $ | 0.37 % |
| 50 | Xencor Inc | 200,000 | 2.4M $ | 0.36 % |
| 51 | Day One Biopharmaceuticals Inc | 110,000 | 2.4M $ | 0.35 % |
| 52 | Compugen Ltd | 1,020,000 | 2.2M $ | 0.33 % |
| 53 | ACADIA Pharmaceuticals Inc | 92,648 | 2.1M $ | 0.31 % |
| 54 | Arvinas Inc | 180,000 | 1.9M $ | 0.29 % |
| 55 | United Therapeutics Corp | 3,000 | 1.8M $ | 0.27 % |
| 56 | BioNTech SE | 18,000 | 1.6M $ | 0.24 % |
| 57 | Coherus Oncology Inc | 900,000 | 1.5M $ | 0.23 % |
| 58 | MoonLake Immunotherapeutics | 80,000 | 1.5M $ | 0.22 % |
| 59 | COSMO Pharmaceuticals NV | 14,000 | 1.5M $ | 0.22 % |
| 60 | Ultragenyx Pharmaceutical Inc | 70,000 | 1.5M $ | 0.22 % |
| 61 | REGENXBIO Inc | 149,000 | 1.2M $ | 0.19 % |
| 62 | Nektar Therapeutics | 17,092 | 1.2M $ | 0.18 % |
| 63 | MacroGenics Inc | 420,000 | 1.2M $ | 0.18 % |
| 64 | Vaxcyte Inc | 20,000 | 1.2M $ | 0.17 % |
| 65 | Janux Therapeutics Inc | 76,601 | 1.1M $ | 0.16 % |
| 66 | Moderna Inc | 20,000 | 1M $ | 0.15 % |
| 67 | PROQR THERAPEUTICS NV | 620,000 | 1M $ | 0.15 % |
| 68 | Cytokinetics Inc | 15,000 | 988.7K $ | 0.15 % |
| 69 | Olema Pharmaceuticals Inc | 50,000 | 745.5K $ | 0.11 % |
| 70 | Cellectis SA | 226,875 | 719.2K $ | 0.11 % |
| 71 | WaVe Life Sciences Ltd | 81,955 | 594.2K $ | 0.09 % |
| 72 | Viridian Therapeutics Inc | 29,370 | 574.5K $ | 0.09 % |
| 73 | Instil Bio Inc | 50,000 | 412K $ | 0.06 % |
| 74 | Puma Biotechnology Inc | 61,255 | 391.4K $ | 0.06 % |
| 75 | Atea Pharmaceuticals Inc | 70,000 | 376.6K $ | 0.06 % |
| 76 | Allogene Therapeutics Inc | 146,779 | 358.1K $ | 0.05 % |
| 77 | Altimmune Inc | 100,000 | 308K $ | 0.05 % |
| 78 | Intellia Therapeutics Inc | 20,000 | 256.4K $ | 0.04 % |
| 79 | Sarepta Therapeutics Inc | 11,000 | 239.4K $ | 0.04 % |
| 80 | Myriad Genetics Inc | 50,000 | 225K $ | 0.03 % |
| 81 | Rocket Pharmaceuticals Inc | 58,000 | 207.6K $ | 0.03 % |
| 82 | Karyopharm Therapeutics Inc | 33,333 | 185.7K $ | 0.03 % |
| 83 | Organon & Co | 29,500 | 176.7K $ | 0.03 % |
| 84 | Amarin Corp PLC | 9,500 | 137.4K $ | 0.02 % |
| 85 | NextCure Inc | 12,500 | 131.5K $ | 0.02 % |
| 86 | XOMA Royalty Corp | 3,466 | 108.7K $ | 0.02 % |
| 87 | Sangamo Therapeutics Inc | 400,000 | 98.8K $ | 0.01 % |
| 88 | PHIO PHARMACEUTICALS CORP | 50,000 | 61K $ | 0.01 % |
| 89 | LITE STRATEGY INC | 30,000 | 34.8K $ | 0.01 % |
| 90 | InnoCare Pharma Ltd | 17,000 | 29.6K $ | 0.00 % |
| 91 | Voyager Therapeutics Inc | 5,700 | 22K $ | 0.00 % |
| 92 | Fortress Biotech Inc | 6,666 | 18.6K $ | 0.00 % |
| 93 | Akero Therapeutics Inc | 25,000 | 16.3K $ | 0.00 % |
| 94 | Euroapi SA | 8,695 | 13.3K $ | 0.00 % |
| 95 | Galmed Pharmaceuticals Ltd | 1,701 | 821.9 $ | 0.00 % |
| 96 | MUSTANG BIO INC | 160 | 116.5 $ |
Sector breakdown
- Health care 66.5 %
- Unattributed 33.5 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 83.4 %
- EUR 8.2 %
- GBP 4.1 %
- JPY 4.0 %
- CHF 0.2 %
The quoted currency of each line, as declared.
Country breakdown
- United States 77.1 %
- Belgium 6.3 %
- United Kingdom 4.2 %
- Japan 4.0 %
- France 2.8 %
- Ireland 2.3 %
- Bermuda 1.5 %
- Netherlands 0.8 %
- Israel 0.4 %
- Germany 0.3 %
- Cayman Islands 0.2 %
- Singapore 0.1 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 76 | 478.5M $ | 77.13 % |
| 2 | Belgium | 1 | 39.2M $ | 6.32 % |
| 3 | United Kingdom | 2 | 25.8M $ | 4.16 % |
| 4 | Japan | 1 | 24.8M $ | 4.00 % |
| 5 | France | 4 | 17.3M $ | 2.79 % |
| 6 | Ireland | 3 | 14.2M $ | 2.29 % |
| 7 | Bermuda | 1 | 9.4M $ | 1.51 % |
| 8 | Netherlands | 2 | 5.2M $ | 0.84 % |
| 9 | Israel | 2 | 2.2M $ | 0.35 % |
| 10 | Germany | 1 | 1.6M $ | 0.26 % |
| 11 | Cayman Islands | 1 | 1.5M $ | 0.24 % |
| 12 | Singapore | 1 | 594.2K $ | 0.10 % |
Cite this page
Titelia. "Holdings of Nomura Healthcare Fund". https://titelia.com/en/funds/S000018873